Cid, Joan <br/><br/>
Rituximab, plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness.  [electronic resource] 

 -  Platelets  2015 
 - 190-4 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Review 
<br/><br/><label>ISSN: </label>1369-1635 
<br/><br/><label>Standard No.: </label>10.3109/09537104.2014.895922  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Murine-Derived--therapeutic use<br/>Antigens, Human Platelet--immunology<br/>Blood Platelet Disorders--blood<br/>Female<br/>HLA Antigens--immunology<br/>Humans<br/>Immunoglobulins, Intravenous<br/>Immunologic Factors--therapeutic use<br/>Middle Aged<br/>Plasma Exchange<br/>Platelet Count<br/>Platelet Transfusion--adverse effects<br/>Rituximab<br/>Treatment Outcome